Monthly Archives: July 2011

Leniency and Flexibility: The Optimum Conditions for Innovation

By Guest Blogger | Published: July 14, 2011
Leniency and staff reward/recognition are key to improving R&D and product innovation, according to the first of three new Economist Intelligence Unit reports. Innovation Imperative in Biopharma focuses on the how to curb wasteful R&D spending and how to strengthen innovation abilities. The study is based on a survey of 282 senior executives, each of [...]
Posted in Global, Guest Blog, People, R&D, Strategy | Tagged , | Leave a comment

So, Where Are We with ACOs?

By Guest Blogger | Published: July 13, 2011
Tom Norton gets to grips with what an Accountable Care Organization is … and what it is not. Sixteen months into the new Healthcare Reform law, many continue to wonder about the status one of the most confused aspects of the new HCR — the elusive Accountable Care Organization, or ACO. And why are ACOs viewed [...]
Posted in Guest Blog, Regulatory | Tagged , , , , , | 2 Comments

Pharma to Flash the Cash to Counter Bleak Short-Term Outlook

By Julian Upton | Published: July 13, 2011
Nearly two-thirds of US senior pharmaceutical executives surveyed by last month foresee a ‘full economic recovery’ by the end of 2013, with more than half of these pointing to an upturn in the industry’s fortunes by the end of next year. However, 27 percent of the 100 executives interviewed by KPMG for its Industry Pulse Survey [...]
Posted in Strategy | Tagged , , , , | Leave a comment

GSK Reps Trade Sales Targets for Sales Competencies

By Ben Comer | Published: July 5, 2011
Last summer, GlaxoSmithKline announced plans to upend the pay structure for its US-based sales reps by removing incentives based on hard sales figures, or how many pills are sold. Instead of rewarding reps for the amount of product sold, GSK would begin rewarding reps for the quality of relationship they engender, the company said.
Posted in Marketing, Sales | Tagged , , | 1 Comment